|
A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 (Catalog No. 14650), which is known to have a short plasma half-life.2,3,4 13,14-dihydro-15-keto tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 (Catalog No. 14650), which is known to have a short plasma half-life.2,3,4
|
|
1
Hamberg, M. Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun 49 720-726 (1972).
2
Bothwell, W., Verburg, M., Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics. J Pharmacol Exp Ther 220 229-235 (1982).
3
Fitzpatrick, F.A., Aguirre, R., Pike, J.E., et al. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins 19 917-931 (1980).
4
Granström, E., Hamberg, M., Hansson, G., et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability. Prostaglandins 19 933-945 (1980).
|